CD19 and diffuse large B-cell lymphoma: No significant improvement in CR was observed with various CAR-T configurations in relapsed/refractory DLBCL, including CD28/CD19/CD20 and 41BB/CD19/CD20 CAR-T, underscoring the need for further optimization to address resistance and enhance long-term outcomes (89).The umbrella review found no significant difference in OS between Axi-cel and Tisa-ce, suggesting that although Axi-cel may demonstrate superior efficacy in certain aspects, it does not confer a survival benefit.